<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512262</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-019</org_study_id>
    <secondary_id>ATOM</secondary_id>
    <nct_id>NCT03512262</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12 month study to measure the efficacy and safety of abaloparatide in men with&#xD;
      osteoporosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this prospective controlled study is to evaluate the efficacy and&#xD;
      the safety of abaloparatide-SC 80 mcg per day compared to placebo as assessed by change in&#xD;
      bone mineral density over 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2018</start_date>
  <completion_date type="Actual">September 8, 2021</completion_date>
  <primary_completion_date type="Actual">September 8, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized patients will received a 2:1 ratio of abaloparatide:placebo injections.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment will be blinded to participants, investigators, outcome Assessor and care provider throughout the study except in a medical emergency where the identity of study medication is necessary to appropriately treat the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar spine bone mineral density (BMD)</measure>
    <time_frame>12 months</time_frame>
    <description>Percent change from baseline in lumbar spine BMD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total hip BMD</measure>
    <time_frame>12 months</time_frame>
    <description>Percent change from baseline for total hip BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral neck BMD</measure>
    <time_frame>12 months</time_frame>
    <description>Percent change from baseline for femoral neck BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar spine BMD</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline in lumbar spine BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) associated with hypercalcemia</measure>
    <time_frame>13 months</time_frame>
    <description>Percent of participants reporting TEAE associated with hypercalcemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Osteoporosis, Age-Related</condition>
  <condition>Osteoporosis Localized to Spine</condition>
  <condition>Age Related Osteoporosis</condition>
  <condition>Osteoporosis Senile</condition>
  <condition>Osteoporosis of Vertebrae</condition>
  <arm_group>
    <arm_group_label>Abaloparatide (BA058)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abaloparatide is an active synthetic peptide of parathyroid hormone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with no peptide of parathyroid hormone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abaloparatide</intervention_name>
    <description>Abaloparatide 80 mcg subcutaneous daily</description>
    <arm_group_label>Abaloparatide (BA058)</arm_group_label>
    <other_name>TYMLOS®</other_name>
    <other_name>BA058</other_name>
    <other_name>abaloparatide-SC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 0 mcg subcutaneous daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Healthy ambulatory male from 40 to 85 years of age (inclusive) with primary&#xD;
             osteoporosis or osteoporosis associated with hypogonadism.&#xD;
&#xD;
          -  The patient has a BMD T-score (based on the female reference range as assessed by the&#xD;
             central imaging vendor) of ≤ -2.5 at the lumbar spine (L1-L4) or hip (femoral neck or&#xD;
             total hip) by DXA or ≤-1.5 and with radiologic evidence of vertebral fracture or a&#xD;
             documented history of low-trauma nonvertebral fracture sustained in the past 5 years.&#xD;
             Men older than 65 years may be enrolled if they have a BMD T-score ≤ -2.0 even if they&#xD;
             do not meet the fracture criteria.&#xD;
&#xD;
          -  Normal medical history, physical examination, including vital signs, and body mass&#xD;
             index (BMI).&#xD;
&#xD;
          -  Hypogonadal patients whose doses of androgens have been stable for at least twelve&#xD;
             months before randomization are eligible and may continue therapy during the study.&#xD;
&#xD;
          -  Laboratory tests within the normal range including serum calcium (albumin-corrected),&#xD;
             PTH, serum phosphorus and alkaline phosphatase, and thyroid stimulating hormone (TSH)&#xD;
             values.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Presence of abnormalities of the lumbar spine that would prohibit assessment of spinal&#xD;
             bone mineral density, defined as having at least 2 radiologically evaluable vertebrae&#xD;
             within L1-L4.&#xD;
&#xD;
          -  A BMD T-score of ≤-3.5 at the total hip, femoral neck, or lumbar spine based upon the&#xD;
             female reference range.&#xD;
&#xD;
          -  Unevaluable hip BMD or patients who have undergone bilateral hip replacement.&#xD;
&#xD;
          -  Fragility fracture within the prior twelve months.&#xD;
&#xD;
          -  History of severe vertebral fracture or &gt;2 moderate vertebral fractures.&#xD;
&#xD;
          -  History of bone disorders (e.g., Paget's disease) other than osteoporosis.&#xD;
&#xD;
          -  Patients with clinical signs of hypogonadism present at screening who plan to initiate&#xD;
             testosterone replacement.&#xD;
&#xD;
          -  History of prior external beam or implant radiation therapy involving the skeleton&#xD;
             other than radioiodine.&#xD;
&#xD;
          -  History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular,&#xD;
             gastrointestinal, endocrine, central nervous system, hematologic or metabolic&#xD;
             diseases, or immunologic, emotional and/or psychiatric disturbances to a degree that&#xD;
             would interfere with the interpretation of study data or compromise the safety of the&#xD;
             patient.&#xD;
&#xD;
          -  History of Cushing's disease, growth hormone deficiency or excess, hyperthyroidism,&#xD;
             hypo- or hyperparathyroidism or malabsorptive syndromes within the past year.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Director, Clinical Operations</last_name>
    <role>Study Director</role>
    <affiliation>Radius Health, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marin Endocrine Care &amp; Research, Inc.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta California Medical Group</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panorama Orthopedics &amp; Spine Center</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indago Research &amp; Health Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Diabetes Associates, Pa</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Advanced Research &amp; Education</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Mexico Clinical Research &amp; Osteoporosis Center, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Cary, LLC</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies, Inc</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Osteoporosis Clinical Research Program</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <state>Tuscany</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda ospedaliera universitaria integrata di verona(AOUI)</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne Sp. z o.o.</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp. z o.o. Oddzial w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdrowie Osteo-Medic s.c. Lidia I Artur Racewicz, Agnieszka I Jerzy Supronik</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk, Nowak Sp.j.</name>
      <address>
        <city>Białystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETG Siedlce</name>
      <address>
        <city>Siedlce</city>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Nasz Lekarz</name>
      <address>
        <city>Toruń</city>
        <zip>87100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Polska Sp z o.o Oddzial we Wroclawiu</name>
      <address>
        <city>Wrocław</city>
        <zip>50-381</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Leczenia Osteoporozy Klinika Zdrowej Kosci</name>
      <address>
        <city>Łódź</city>
        <zip>90-558</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and hormones. J Mol Endocrinol. 2001 Apr;26(2):79-94. Review.</citation>
    <PMID>11241160</PMID>
  </reference>
  <reference>
    <citation>Mannstadt M, Jüppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol. 1999 Nov;277(5):F665-75. doi: 10.1152/ajprenal.1999.277.5.F665. Review.</citation>
    <PMID>10564229</PMID>
  </reference>
  <reference>
    <citation>Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993 Dec;14(6):690-709. Review. Erratum in: Endocr Rev 1994 Apr;15(2):261.</citation>
    <PMID>8119233</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BA058</keyword>
  <keyword>abaloparatide</keyword>
  <keyword>abaloparatide-SC</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>male osteoporosis</keyword>
  <keyword>TYMLOS™</keyword>
  <keyword>fracture</keyword>
  <keyword>bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abaloparatide</mesh_term>
    <mesh_term>Parathyroid Hormone-Related Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

